Precision BioSciences Expands ELIMINATE-B Trial with France and Romania Sites, Screening Q2 2026
Precision BioSciences received CTA approval to expand its global ELIMINATE-B trial into France and Romania, adding to existing sites in the UK, Moldova, New Zealand, Hong Kong and the US. Site initiation is underway with initial patient screening for PBGENE-HBV expected in Q2 2026.
1. Clinical Trial Application Approvals
Precision BioSciences secured regulatory authorizations in France and Romania to expand its global ELIMINATE-B trial of PBGENE-HBV following CTA approvals, enabling legal initiation of study activities in these countries.
2. Trial Expansion and Patient Enrollment
The trial extension adds to existing sites in the UK, Moldova, New Zealand, Hong Kong and the US, with site initiation underway and initial patient screening slated for Q2 2026 to accelerate enrollment.
3. PBGENE-HBV Program and Potential Impact
PBGENE-HBV is an in vivo gene editing therapy designed to eliminate HBV cccDNA and integrated viral fragments, holding FDA Fast Track designation and aiming for a functional cure in chronic hepatitis B.